Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis.

Abstract

The safety profile of the novel oral JAK2/IRAK1 inhibitor pacritinib in patients with cytopenic myelofibrosis was described in the Phase 2 PAC203 and Phase 3 PERSIST-2 studies. To account for longer treatment durations on the pacritinib arms compared to best available therapy (BAT), we present a risk-adjusted safety analysis of event rates accounting for different time on treatment. While the rate of overall events was higher on pacritinib compared to BAT, the rate of fatal events was lower, and there was no excess in bleeding, cardiac events, secondary malignancy, or thrombosis on pacritinib, including in patients with severe thrombocytopenia.

• Authors: Naveen Pemmaraju, Claire Harrison, Vikas Gupta, Srdan Verstovsek, Bart Scott, Stephen T Oh, Francesca Palandri, Haifa Kathrin Al-Ali, Marta Sobas, Mary Frances McMullin, Ruben Mesa, Sarah Buckley, Karisse Roman-Torres, Alessandro Vannucchi, Abdulraheem Yacoub
• Journal: EJHaem (EJHaem) Vol. 3 Issue 4 Pg. 1346-1351 (Nov 2022) ISSN: 2688-6146 [Electronic] United States
• PMID: 36467816 (Publication Type: Journal Article)
• Copyright: © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.